English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an enzyme that has been shown to be a risk factor of cardiovascular disease (CVD) and that is involved in the degradation of the phospholipid mediator platelet-activating factor (PAF), a potent mediator of inflammation. The aim of the present study was to investigate concentration of Lp-PLA2 in control group and patients with chronic dental diseases and stable coronary artery disease (CAD). We studied 10 patients with chronic dental diseases, 10 patients with stable coronary artery disease and 10 healthy individuals as controls. Our patients with stable coronary artery disease were using anti-hypertension medicaments, acetylsalicylic acid and statins although patients with chronic dental diseases were not. A plasma Lp-PLA2 assay kit (ELISA, Human, Life Inc., Wuhan, China) was used. Our results showed that both groups of patients with chronic dental diseases and stable coronary artery disease had significantly increased Lp-PLA2 mass as compared to controls. However, Lp-PLA2 mass in patients with chronic dental diseases and stable coronary artery disease was non-significant statistically. We concluded that patients with chronic dental diseases have increased the serum lipoprotein-associated phospholipase A2, which is believed to be an independent cardiovascular risk factor, although future studies are required.

Concentration of lipoprotein - associated phospholipase A2 in chronic dental diseases and stable coronary artery disease